SLC5A2 and atrial septal defect: Nakhal et al. [238] evaluated the therapeutic effects of canagliflozin, the sodium-glucose cotransporter 2 (SGLT2) in the treatment of ASD-like behavior in adolescent rat offspring prenatally exposed to 500 mg/kg VPA on GD 12.5.